The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.
Age range
1 Year
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Percentage of Seropositive Participants at 4 Weeks After Dose 3
Timeframe: 4 weeks after Dose 3
Percentage of Participants With Local Reactions (LR) Within 7 Days After Dose 1
Timeframe: Within 7 days after Dose 1
Percentage of Participants With Local Reactions Within 7 Days After Dose 2
Timeframe: Within 7 days after Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Dose 3
Timeframe: Within 7 days after Dose 3
Percentage of Participants With Systemic Events (SE) Within 7 Days After Dose 1
Timeframe: Within 7 days after Dose 1
Percentage of Participants With Systemic Events Within 7 Days After Dose 2
Timeframe: Within 7 days after Dose 2
Percentage of Participants With Systemic Events Within 7 Days After Dose 3
Timeframe: Within 7 days after Dose 3
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Dose 1
Timeframe: Within 1 month after Dose 1
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Dose 2
Timeframe: Within 1 month after Dose 2
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Dose 3
Timeframe: Within 1 month after Dose 3
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Any Dose
Timeframe: Within 1 month after any Dose
Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study
Timeframe: From Day 1 up to end of study (up to approximately 13 months)